Epsilon Healthcare (ASX:EPN) share price rockets 24% on new agreement

Scientists are still unlocking the full potential of medicinal marijuana.

| More on:
Back view of a man lifting hish hands high in front of hemp plants grown for cannabis.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Epsilon Healthcare Ltd (ASX: EPN) share price is off to the races today, currently up 20% at 15 cents apiece after hitting an intraday high of 16.5 cents at midday.

Below, we take a look at the new manufacturing agreement that appears to be spurring investor interest in the ASX medicinal cannabis company.

What new manufacturing agreement was announced?

Epsilon Healthcare's share price is soaring after the company reported it has executed a binding term sheet and manufacturing agreement with Cannim Australia Pty Ltd.

Cannim, established in 2017, cultivates cannabis in Jamaica and Australia. The privately held company has engaged Epsilon as its Australian GMP manufacturing partner.

Epsilon's Southport Facility in Queensland will produce medicinal cannabis products from marijuana supplied by Cannim for supply into Australian and global export. Epsilon will receive payment from Cannim for its manufacturing services on a per-order basis

The initial agreement runs for 2 years.

According to the release, the first cannabis derived dried flower products have already been delivered and are available to patients by Epsilon under Cannim's HummingBud brand.

Under the binding term sheet, the companies have agreed to further collaboration and manufacture over next 2 years.

Management commentary

Commenting on the agreement, Epsilon Healthcare CEO Jarrod White said:

Matching our high-volume EU GMP compliant Southport Facility with Cannim's high volume GACP Jamaican medicinal cannabis places both companies in a strong position to deliver significant volumes of high-quality medicines for both the Australian and global export markets.

The partnership contemplates all areas of the Epsilon value chain, from local import and handling of dried product expertise, to export, and assisting in the logistics and distribution of the final product. This is reflective of the significant progress and capability improvements at our Southport facility in the preceding 12 months.

Epsilon Healthcare share price snapshot

Despite today's big boost, the Epsilon Healthcare share price remains down 36% year-to-date. By comparison the All Ordinaries Index (ASX: XAO) is up 12% so far in 2020.

The last month has been kinder to Epsilon Healthcare shareholders, with shares up 19% since 21 September.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »